244 related articles for article (PubMed ID: 26488033)
1. Filgrastim for the treatment of hematopoietic acute radiation syndrome.
Farese AM; MacVittie TJ
Drugs Today (Barc); 2015 Sep; 51(9):537-48. PubMed ID: 26488033
[TBL] [Abstract][Full Text] [Related]
2. An update on sargramostim for treatment of acute radiation syndrome.
Singh VK; Seed TM
Drugs Today (Barc); 2018 Nov; 54(11):679-693. PubMed ID: 30539167
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Neulasta or Neupogen on H-ARS and GI-ARS Mortality and Hematopoietic Recovery in Nonhuman Primates After 10-Gy Irradiation With 2.5% Bone Marrow Sparing.
Farese AM; Bennett AW; Gibbs AM; Hankey KG; Prado K; Jackson W; MacVittie TJ
Health Phys; 2019 Mar; 116(3):339-353. PubMed ID: 30281533
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice.
Lee CL; Lento WE; Castle KD; Chao NJ; Kirsch DG
Radiat Res; 2014 May; 181(5):445-51. PubMed ID: 24720754
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Radiation Dose and Variation in Neupogen® Initiation Schedule on the Mitigation of Myelosuppression during the Concomitant GI-ARS and H-ARS in a Nonhuman Primate Model of High-dose Exposure with Marrow Sparing.
MacVittie TJ; Bennett AW; Farese AM; Taylor-Howell C; Smith CP; Gibbs AM; Prado K; Jackson W
Health Phys; 2015 Nov; 109(5):427-39. PubMed ID: 26425903
[TBL] [Abstract][Full Text] [Related]
6. Biologics as countermeasures for acute radiation syndrome: where are we now?
Singh VK; Romaine PL; Newman VL
Expert Opin Biol Ther; 2015 Apr; 15(4):465-71. PubMed ID: 25416452
[TBL] [Abstract][Full Text] [Related]
7. The Gottingen minipig is a model of the hematopoietic acute radiation syndrome: G-colony stimulating factor stimulates hematopoiesis and enhances survival from lethal total-body γ-irradiation.
Moroni M; Ngudiankama BF; Christensen C; Olsen CH; Owens R; Lombardini ED; Holt RK; Whitnall MH
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):986-92. PubMed ID: 23845847
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
9. Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors.
Chua HL; Plett PA; Sampson CH; Katz BP; Carnathan GW; MacVittie TJ; Lenden K; Orschell CM
Health Phys; 2014 Jan; 106(1):21-38. PubMed ID: 24276547
[TBL] [Abstract][Full Text] [Related]
10. Totality of the evidence at work: The first U.S. biosimilar.
Holzmann J; Balser S; Windisch J
Expert Opin Biol Ther; 2016; 16(2):137-42. PubMed ID: 26634611
[TBL] [Abstract][Full Text] [Related]
11. Neulasta Regimen for the Hematopoietic Acute Radiation Syndrome: Effects Beyond Neutrophil Recovery.
Legesse B; Kaur A; Kenchegowda D; Hritzo B; Culp WE; Moroni M
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):935-944. PubMed ID: 30496878
[TBL] [Abstract][Full Text] [Related]
12. Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study.
Tamura K; Hashimoto K; Nishikawa K
J Infect Chemother; 2018 May; 24(5):363-369. PubMed ID: 29398477
[TBL] [Abstract][Full Text] [Related]
13. γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.
Singh VK; Hauer-Jensen M
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27153057
[TBL] [Abstract][Full Text] [Related]
14. An update on romiplostim for treatment of acute radiation syndrome.
Singh VK; Seed TM
Drugs Today (Barc); 2022 Mar; 58(3):133-145. PubMed ID: 35274632
[TBL] [Abstract][Full Text] [Related]
15. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.
Singh VK; Romaine PL; Newman VL; Seed TM
Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458
[TBL] [Abstract][Full Text] [Related]
16. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review.
Singh VK; Newman VL; Seed TM
Cytokine; 2015 Jan; 71(1):22-37. PubMed ID: 25215458
[TBL] [Abstract][Full Text] [Related]
17. Impact of Abbreviated Filgrastim Schedule on Survival and Hematopoietic Recovery after Irradiation in Four Mouse Strains with Different Radiosensitivity.
Satyamitra M; Kumar VP; Biswas S; Cary L; Dickson L; Venkataraman S; Ghosh SP
Radiat Res; 2017 Jun; 187(6):659-671. PubMed ID: 28362168
[TBL] [Abstract][Full Text] [Related]
18. Delayed Captopril Administration Mitigates Hematopoietic Injury in a Murine Model of Total Body Irradiation.
McCart EA; Lee YH; Jha J; Mungunsukh O; Rittase WB; Summers TA; Muir J; Day RM
Sci Rep; 2019 Feb; 9(1):2198. PubMed ID: 30778109
[TBL] [Abstract][Full Text] [Related]
19. The benefits and drawbacks of biosimilars.
Cronstein BN
Clin Adv Hematol Oncol; 2015 Oct; 13(10):639-41. PubMed ID: 27058566
[No Abstract] [Full Text] [Related]
20. Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond.
Singh VK; Seed TM
Int J Radiat Biol; 2021; 97(11):1526-1547. PubMed ID: 34402734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
